Lipodystrophy syndromes should be considered when metabolic symptoms are disproportionate to body size, including diabetes with high insulin requirements, hypertriglyceridemia, fatty liver disease, or polycystic ovary syndrome (PCOS). This evidence concerns the gene INS and polycystic ovary syndrome.